Financial toxicity in hematological malignancies: a systematic review
Abstract Hematologic malignancy outcomes have remarkably improved in the past decade with further advancement expected in future years. However, the detrimental effects of financial toxicity (FT) on patients with hematologic malignancies, because of both diagnoses and subsequent treatments, have not...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2022-04-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-022-00671-z |
| _version_ | 1818147349521760256 |
|---|---|
| author | Evguenia Ouchveridze Rahul Banerjee Aakash Desai Muhammad Aziz Wade Lee-Smith Hira Mian Katherine Berger Brian McClune Douglas Sborov Muzaffar Qazilbash Shaji Kumar Ghulam Rehman Mohyuddin |
| author_facet | Evguenia Ouchveridze Rahul Banerjee Aakash Desai Muhammad Aziz Wade Lee-Smith Hira Mian Katherine Berger Brian McClune Douglas Sborov Muzaffar Qazilbash Shaji Kumar Ghulam Rehman Mohyuddin |
| author_sort | Evguenia Ouchveridze |
| collection | DOAJ |
| description | Abstract Hematologic malignancy outcomes have remarkably improved in the past decade with further advancement expected in future years. However, the detrimental effects of financial toxicity (FT) on patients with hematologic malignancies, because of both diagnoses and subsequent treatments, have not been studied comprehensively. We performed a systematic review of all studies reporting FT as a primary or secondary outcome among adult or pediatric patients with hematological malignancies. A total of 55 studies met the inclusion criteria for analysis. Across studies, 20–50% of patients reported some form of FT, including loss of work productivity, food and transportation costs, and depletion of savings. Younger age, lower-income level, unemployment, and rural residence were the most commonly identified risk factors for FT. Two studies looked at survival outcomes, with one reporting improvement in survival with a decrease in financial toxicity. However, significant heterogeneity in FT definitions was found between countries and payor systems. Only half of the studies (51%, n = 28) used validated survey instruments such as the COST assessment. The present systematic review identified that FT is common in patients with hematological malignancies and may be associated with poorer outcomes. However, studies of FT generally use non-standardized methods with cross-sectional analyses rather than longitudinal, prospective assessments. Further work is needed to standardize FT reporting and investigate measures to alleviate FT among patients with hematologic malignancies. |
| first_indexed | 2024-12-11T12:33:50Z |
| format | Article |
| id | doaj.art-83d6020ff18240ae9fbce99d4f4d68af |
| institution | Directory Open Access Journal |
| issn | 2044-5385 |
| language | English |
| last_indexed | 2024-12-11T12:33:50Z |
| publishDate | 2022-04-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Blood Cancer Journal |
| spelling | doaj.art-83d6020ff18240ae9fbce99d4f4d68af2022-12-22T01:07:11ZengNature Publishing GroupBlood Cancer Journal2044-53852022-04-011241910.1038/s41408-022-00671-zFinancial toxicity in hematological malignancies: a systematic reviewEvguenia Ouchveridze0Rahul Banerjee1Aakash Desai2Muhammad Aziz3Wade Lee-Smith4Hira Mian5Katherine Berger6Brian McClune7Douglas Sborov8Muzaffar Qazilbash9Shaji Kumar10Ghulam Rehman Mohyuddin11Department of Hematological Malignancies and Cellular Therapeutics, Kansas University Medical CenterDivision of Hematology/Oncology, Department of Medicine, University of California San FranciscoDivision of Hematology, Mayo ClinicMulford Health Science Library, University of ToledoMulford Health Science Library, University of ToledoDepartment of Oncology, McMaster UniversityPatient Advocate, University of HartfordDivision of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of UtahDivision of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of UtahDivision of Transplant, University of Texas MD Anderson Cancer CenterDivision of Hematology, Mayo ClinicDivision of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of UtahAbstract Hematologic malignancy outcomes have remarkably improved in the past decade with further advancement expected in future years. However, the detrimental effects of financial toxicity (FT) on patients with hematologic malignancies, because of both diagnoses and subsequent treatments, have not been studied comprehensively. We performed a systematic review of all studies reporting FT as a primary or secondary outcome among adult or pediatric patients with hematological malignancies. A total of 55 studies met the inclusion criteria for analysis. Across studies, 20–50% of patients reported some form of FT, including loss of work productivity, food and transportation costs, and depletion of savings. Younger age, lower-income level, unemployment, and rural residence were the most commonly identified risk factors for FT. Two studies looked at survival outcomes, with one reporting improvement in survival with a decrease in financial toxicity. However, significant heterogeneity in FT definitions was found between countries and payor systems. Only half of the studies (51%, n = 28) used validated survey instruments such as the COST assessment. The present systematic review identified that FT is common in patients with hematological malignancies and may be associated with poorer outcomes. However, studies of FT generally use non-standardized methods with cross-sectional analyses rather than longitudinal, prospective assessments. Further work is needed to standardize FT reporting and investigate measures to alleviate FT among patients with hematologic malignancies.https://doi.org/10.1038/s41408-022-00671-z |
| spellingShingle | Evguenia Ouchveridze Rahul Banerjee Aakash Desai Muhammad Aziz Wade Lee-Smith Hira Mian Katherine Berger Brian McClune Douglas Sborov Muzaffar Qazilbash Shaji Kumar Ghulam Rehman Mohyuddin Financial toxicity in hematological malignancies: a systematic review Blood Cancer Journal |
| title | Financial toxicity in hematological malignancies: a systematic review |
| title_full | Financial toxicity in hematological malignancies: a systematic review |
| title_fullStr | Financial toxicity in hematological malignancies: a systematic review |
| title_full_unstemmed | Financial toxicity in hematological malignancies: a systematic review |
| title_short | Financial toxicity in hematological malignancies: a systematic review |
| title_sort | financial toxicity in hematological malignancies a systematic review |
| url | https://doi.org/10.1038/s41408-022-00671-z |
| work_keys_str_mv | AT evgueniaouchveridze financialtoxicityinhematologicalmalignanciesasystematicreview AT rahulbanerjee financialtoxicityinhematologicalmalignanciesasystematicreview AT aakashdesai financialtoxicityinhematologicalmalignanciesasystematicreview AT muhammadaziz financialtoxicityinhematologicalmalignanciesasystematicreview AT wadeleesmith financialtoxicityinhematologicalmalignanciesasystematicreview AT hiramian financialtoxicityinhematologicalmalignanciesasystematicreview AT katherineberger financialtoxicityinhematologicalmalignanciesasystematicreview AT brianmcclune financialtoxicityinhematologicalmalignanciesasystematicreview AT douglassborov financialtoxicityinhematologicalmalignanciesasystematicreview AT muzaffarqazilbash financialtoxicityinhematologicalmalignanciesasystematicreview AT shajikumar financialtoxicityinhematologicalmalignanciesasystematicreview AT ghulamrehmanmohyuddin financialtoxicityinhematologicalmalignanciesasystematicreview |